Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Healthcare Shares
Up 810% in a year, the Mesoblast share price is surging again on Monday. Here's why
Healthcare Shares
Mesoblast share price rips 12% on financial and operational updates
Broker Notes
5 ASX All Ords shares upgraded to 'strong buy' consensus ratings
Share Fallers
Why Block, Canyon, Fisher & Paykel Healthcare, and Mesoblast shares are falling today
Share Gainers
3 ASX All Ords stocks smashing the benchmark this week
Share Market News
Why Lendlease, Mesoblast, St Barbara, and Zip shares are pushing higher
Healthcare Shares
Up 1,090% in a year, why is the Mesoblast share price leaping higher again on Friday?
Healthcare Shares
$1,000 invested in Mesoblast shares at the start of 2024 is now worth…
Healthcare Shares
Up 19% in a month, what's driving Mesoblast shares?
Healthcare Shares
Mesoblast shares dip then flip on $800,000 insider buy
Share Fallers
Why Mesoblast, Myer, Premier Investments, and Vulcan shares are falling today
Healthcare Shares
Why is the Mesoblast share price crashing 9% today?
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
